Biotech · Private company · Austin, TX, US
Via Therapeutics, LLC
Track this companyFree. Adds Via Therapeutics, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards9
- Dry powders of whole blood prepared by thin-film freeze-dryingFiscal year 2026 · $315.1KNIH RePORTER 1R41HL186958-01 · fetched Nov 12, 2026
- Development of Macrophage Targeting Inhaled Tigecycline Dry Powder Formulation for Treating Non-Tuberculous Mycobacterial (NTM) InfectionsFiscal year 2026 · $313.7KNIH RePORTER 1R43AI197715-01 · fetched Nov 12, 2026
- Novel Ocular Aerosol Drug Delivery Device for the Treatment Optimization of Glaucoma.Fiscal year 2026 · $277.1KNIH RePORTER 1R43EY038569-01 · fetched Nov 12, 2026
- Development of dermal targeting formulations for squamous cell carcinomaFiscal year 2026 · $660.8KNIH RePORTER 2R44CA257783-02A1 · fetched Nov 12, 2026
- Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenzaFiscal year 2026 · $971.3KNIH RePORTER 5R44AI174337-03 · fetched Nov 12, 2026
- Microneedle-based mRNA Flu Vaccine for Transcutaneous ImmunizationFiscal year 2025 · $314.4KNIH RePORTER 1R41AI195038-01 · fetched Nov 12, 2026
- Combined Amikacin and Azithromycin in an Inhaled Formulation for the Treatment of NTMFiscal year 2025 · $314.4KNIH RePORTER 1R41AI195081-01 · fetched Nov 12, 2026
- Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenzaFiscal year 2025 · $1MNIH RePORTER 7R44AI174337-02 · fetched Nov 12, 2026
- Inhalable dry powders of mycobacteriophages for tuberculosis therapyFiscal year 2024 · $300KNIH RePORTER 1R41AI186644-01 · fetched Nov 12, 2026